SAB Biotherapeutics (SABS) Long-Term Investments (2021 - 2026)

SAB Biotherapeutics (SABS) has 4 years of Long-Term Investments data on file, last reported at $110.2 million in Q1 2026.

• Quarterly Long-Term Investments changed N/A year-over-year to $110.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $110.2 million (changed N/A YoY) and the FY2025 annual result came in at $46.9 million, changed N/A from the prior year.
• Long-Term Investments grew to $110.2 million in Q1 2026, from $46.9 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $110.2 million in Q1 2026 to a low of $1.2 million in Q1 2024.
• A 3-year average of $52.2 million and a median of $48.8 million in 2025 frame the typical range for Long-Term Investments.